Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z

Diabetic medicine : a journal of the British Diabetic Association1 Oct 2012Cited by 84 (Europe PMC)

PMID22804250DOI10.1111/j.1464-5491.2012.03745.xPepBankPUB-22804250

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 0.5 mg reduced HbA1c more than placebo.
In plain wordsIn type 2 diabetes, dulaglutide 0.5 mg lowered HbA1c more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg weekly · injection · 12 weeksAs given in this study (human).
Measurements
HbA1c change
−0.9%
dulaglutide 0.5 mg
HbA1c change
−10 mmol/mol
dulaglutide 0.5 mg
HbA1c change
0%
placebo
HbA1c change
0 mmol/mol
placebo
Source sentences
Summary
HbA(1c) reductions in the 0.5, 1.0 and 1.5 mg dulaglutide groups were greater than in the placebo group [-10 ± 1, -11 ± 1 and -11 ± 1 vs. 0 ± 1 mmol/mol (-0.9 ± 0.1, -1.0 ± 0.1 and -1.0 ± 0.1 vs. 0.0 ± 0.1%), respectively, all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425001
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.0 mg reduced HbA1c more than placebo.
In plain wordsIn type 2 diabetes, dulaglutide 1.0 mg lowered HbA1c more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg weekly · injection · 12 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
dulaglutide 1.0 mg
HbA1c change
−11 mmol/mol
dulaglutide 1.0 mg
HbA1c change
0%
placebo
HbA1c change
0 mmol/mol
placebo
Source sentences
Summary
HbA(1c) reductions in the 0.5, 1.0 and 1.5 mg dulaglutide groups were greater than in the placebo group [-10 ± 1, -11 ± 1 and -11 ± 1 vs. 0 ± 1 mmol/mol (-0.9 ± 0.1, -1.0 ± 0.1 and -1.0 ± 0.1 vs. 0.0 ± 0.1%), respectively, all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425002
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.5 mg reduced HbA1c more than placebo.
In plain wordsIn type 2 diabetes, dulaglutide 1.5 mg lowered HbA1c more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · injection · 12 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
dulaglutide 1.5 mg
HbA1c change
−11 mmol/mol
dulaglutide 1.5 mg
HbA1c change
0%
placebo
HbA1c change
0 mmol/mol
placebo
Source sentences
Summary
HbA(1c) reductions in the 0.5, 1.0 and 1.5 mg dulaglutide groups were greater than in the placebo group [-10 ± 1, -11 ± 1 and -11 ± 1 vs. 0 ± 1 mmol/mol (-0.9 ± 0.1, -1.0 ± 0.1 and -1.0 ± 0.1 vs. 0.0 ± 0.1%), respectively, all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425003
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, the fasting glucose difference for dulaglutide 0.1 mg had a 95% confidence interval spanning zero.
In plain wordsIn type 2 diabetes, dulaglutide 0.1 mg did not clearly reduce fasting blood glucose compared with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedFasting plasma glucose
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1 mg weekly · injection · 12 weeksAs given in this study (human).
Measurements
Fasting glucose difference
−0.43 mmol/l
dulaglutide 0.1 mg versus placebo
Source sentences
Summary
Dose-dependent reductions in fasting plasma glucose were also observed [least squares mean difference (95% CI) ranging from -0.43 (-1.06 to 0.19) mmol/l for dulaglutide 0.1 mg to -1.87 (-2.56 to -1.19) mmol/l for dulaglutide 1.5 mg, P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425004
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, no dulaglutide dose differed from placebo in weight loss despite a dose-dependent trend.
In plain wordsIn type 2 diabetes, weight loss showed a dose trend, but no dulaglutide group differed from placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBody weight
Study
n: not reported in source
Comparator
placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
Dose-dependent weight loss was demonstrated across doses (P = 0.009), but none of the groups were different from placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425005
06HumanRandomized controlled trialSafety outcome
In type 2 diabetes treated with dulaglutide, nausea and diarrhoea were the most common adverse events.
In plain wordsIn type 2 diabetes treated with dulaglutide, nausea and diarrhoea were the most common side effects.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea and diarrhoea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events were nausea and diarrhoea.
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425006
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.5 mg reduced fasting plasma glucose versus placebo by 1.87 mmol/l.
In plain wordsIn type 2 diabetes, dulaglutide 1.5 mg lowered fasting blood glucose more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · injection · 12 weeksAs given in this study (human).
Measurements
Fasting glucose difference
−1.87 mmol/l
dulaglutide 1.5 mg versus placebo
Source sentences
Summary
Dose-dependent reductions in fasting plasma glucose were also observed [least squares mean difference (95% CI) ranging from -0.43 (-1.06 to 0.19) mmol/l for dulaglutide 0.1 mg to -1.87 (-2.56 to -1.19) mmol/l for dulaglutide 1.5 mg, P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 12-week, double-blind, placebo-controlled, dose-response trial randomized 167 patients who were anti-hyperglycaemic medication-naïve or had discontinued metformin monotherapy [mean baseline HbA(1c) 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once-weekly injections of placebo or dula…
Report a problemFND-2280425007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00791479

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 167Dec 2008 to Jan 2010

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 10 Dec 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.